International Journal of Clinical Pharmacy

, Volume 36, Issue 2, pp 222–232 | Cite as

A comprehensive review of the impact of clinical pharmacy services on patient outcomes in mental health

  • Tom E. RichardsonEmail author
  • Claire L. O’Reilly
  • Timothy F. Chen
Review Article


Background The importance of pharmacists in mental healthcare is starting to be recognised around the world. However few studies have focused on the evidence supporting pharmacist involvement in the inpatient mental healthcare setting. Aim Evaluate types of outcomes achieved and level of evidence supporting clinical pharmacy services in inpatient mental health settings. Methods Medline, PyscINFO and International Pharmaceutical Abstracts databases were searched from January 1990 to March 31 2013. Studies were included if in an inpatient setting, published in English, and reported an intervention provided by a pharmacist or involving a pharmacist with a pivotal role in an intervention team. Data were extracted according to sample population and size, study design and outline, country, role of the pharmacist in the study, and the main results of the study. The level of evidence for each study was assessed using Australia’s National Health and Medical Research Council’s hierarchy of clinical evidence and results were categorised as having economic, clinical and/or humanistic outcomes. Results Eighteen articles met the inclusion criteria. A range of pharmaceutical services provided by pharmacists in inpatient mental healthcare were identified. These services highlight the role of pharmacists as reviewers of medication charts, laboratory results and medication prescribing and as educators of patients and other health care professionals. Six studies included a control or comparison group and had pre and post intervention measures. These comprised of three randomised control trials, one historical control study and two case series post and pre-post tests, corresponding to evidence levels of II, III-3 and IV respectively. Seven studies reported clinical outcomes, two economical and one humanistic outcomes. One study reported both clinical and economical outcomes. Seven studies focused on impact evaluation measures. Conclusions Pharmacists provide a variety of services and play a significant role in inpatient mental healthcare. However, the level of evidence supporting these services is limited and the type of outcomes achieved is narrow.


Clinical pharmacy Mental health Pharmaceutical services Pharmacists Psychiatry 




Conflicts of interest



  1. 1.
    Kessler RC, Aguilar-Gaxiola S, Alonso J, Chatterji S, Lee S, Ormel J, et al. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psychiatr Soc. 2009;18(1):23–33.CrossRefGoogle Scholar
  2. 2.
    Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013 [cited 29 Oct 2013].
  3. 3.
    Paulose-Ram R, Safran MA, Jonas BS, Gu Q, Orwig D. Trends in psychotropic medication use among U.S. adults. Pharmacoepidemiol Drug Saf. 2007;16(5):560–70.PubMedCrossRefGoogle Scholar
  4. 4.
    Insel TR. Assessing the economic costs of serious mental illness. Am J Psychiatry. 2008;165(6):663–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Pande S, Hiller JE, Nkansah N, Bero L. The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database Syst Rev. 2013;(2).Google Scholar
  6. 6.
    Tan EC, Stewart K, Elliott RA, George J. Pharmacist consultations in general practice clinics: the pharmacists in practice study (PIPS). Res Soc Adm Pharm. 2013 [cited 29 Oct 2013]. Accessed on Oct 29 2013.
  7. 7.
    Castelino RL, Bajorek BV, Chen TF. Retrospective evaluation of home medicines review by pharmacists in older Australian patients using the medication appropriateness index. Ann Pharmacother. 2010;44(12):1922–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Ayorinde AA, Porteous T, Sharma P. Screening for major diseases in community pharmacies: a systematic review. Int J Pharm Pract. Epub 20 May 2013.Google Scholar
  9. 9.
    Tett S, Higgins G, Armour C. Impact of pharmacist interventions on medication management by the elderly: a review of the literature. Ann Pharmacother. 1993;27(1):80–6.PubMedGoogle Scholar
  10. 10.
    Kane S, Weber R, Dasta J. The impact of critical care pharmacists on enhancing patient outcomes. Intensive Care Med. 2003;29(5):691–8.PubMedGoogle Scholar
  11. 11.
    Singhal P, Raisch D, Gupchup G. The impact of pharmaceutical services in community and ambulatory care settings: evidence and recommendations for future research. Ann Pharmacother. 1999;33(12):1336–55.PubMedCrossRefGoogle Scholar
  12. 12.
    Pickard AS, Hung S-Y. An update on evidence of clinical pharmacy services’ impact on health-related quality of life. Ann Pharmacother. 2006;40(9):1623–34.PubMedCrossRefGoogle Scholar
  13. 13.
    Rubio-Valera M, Serrano-Blanco A, Magdalena-Belio J, Fernandez A, Garcia-Campayo J, Pujol MM, et al. Effectiveness of pharmacist care in the improvement of adherence to antidepressants: a systematic review and meta-analysis. Ann Pharmacother. 2011;45(1):39–48.PubMedCrossRefGoogle Scholar
  14. 14.
    Stoner SC, Ott CA, Dipaula BA. Psychiatric pharmacy residency training. Am J Pharm Educ. 2010;74(9):163.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    College of Mental Health Pharmacy. Credentialing—full CMHP membership (MCMHP). 2013; Accessed on Nov 1 2013.
  16. 16.
    College of Mental Health Pharmacy. Membership portfolio—competencies. 2013; Accessed 6 Aug 2013.
  17. 17.
    Australian Pharmacy Council. Statement of mental health care capabilities for pharmacists 2009. Canberra; 2010. Accessed on 6 Aug 2013.
  18. 18.
    Pharmaceutical Society of Australia. Mental health care project: a framework for pharmacists. Canberra; 2013. Accessed on 6 Aug 2013.
  19. 19.
    SHPA Committee of Specialty Practice in Mental Health Pharmacy. Standards of practice for mental health pharmacy. J Pharm Pract Res. 2012;42(2):142–5.Google Scholar
  20. 20.
    Jenkins MH, Bond CA. The impact of clinical pharmacists on psychiatric patients. Pharmacotherapy. 1996;16(4):708–14.PubMedGoogle Scholar
  21. 21.
    Finley PR, Crismon ML, Rush AJ. Evaluating the impact of pharmacists in mental health: a systematic review. Pharmacotherapy. 2003;23(12):1634–44.PubMedCrossRefGoogle Scholar
  22. 22.
    NHMRC. NHMRC additional levels of evidence and grades for recommendations for developers of guidelines. Stage 2 consultation. Early 2008–end June 2009. Canberra: National Health and Medical Research Council; 2009; Accessed 20 May 2013.
  23. 23.
    National Institute for Health and Clinical Excellence. The guidelines manual. London: National Institute for Health and Clinical Excellence; 2007.Google Scholar
  24. 24.
    Khan K, Ter Riet G, Glanville J, Sowden A, Kleijnen J. Undertaking systematic reviews of research on effectiveness. CRD’s guidance for those carrying out or commissioning reviews. York: University of York; 2001.Google Scholar
  25. 25.
    Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, et al. Oxford centre for evidence-based medicine levels of evidence. Oxford: Centre for Evidence-Based Medicine; 2001.Google Scholar
  26. 26.
    Gunter MJ. The role of the ECHO model in outcomes research and clinical practice improvement. Am J Manag Care. 1999;5(4 Suppl):S217–24.PubMedGoogle Scholar
  27. 27.
    Campbell AR, Nelson LA, Elliott E, Hieber R, Sommi RW. Analysis of cost avoidance from pharmacy students’ clinical interventions at a psychiatric hospital. Am J Pharm Educ. 2011;75(1). Article 8.Google Scholar
  28. 28.
    Canales PL, Dorson PG, Crismon ML. Outcomes assessment of clinical pharmacy services in a psychiatric inpatient setting. Am J Health Syst Pharm. 2001;58(14):1309–16.PubMedGoogle Scholar
  29. 29.
    Dolder C, Szymanski B, Wooton T, McKinsey J. Pharmacist interventions in an inpatient geriatric psychiatry unit. Am J Health Syst Pharm. 2008;65(19):1795–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Goad JD, Ezell JR. Drug-use evaluation programs for psychotropic medications. Am J Hosp Pharm. 1990;47(1):132–6.PubMedGoogle Scholar
  31. 31.
    Marino J, Caballero J, Llosent M, Hinkes R. Differences in pharmacy interventions at a psychiatric hospital: comparison of staff pharmacists, pharmacy faculty, and student pharmacists. Hosp Pharm. 2010;45(4):314–9.CrossRefGoogle Scholar
  32. 32.
    McKee J, Cleary S. High-risk, high-alert medication management practices in a regional state psychiatric facility. Hosp Pharm. 2007;42(4):323–30.CrossRefGoogle Scholar
  33. 33.
    Morton WA, Mendenhall AR, Windsor PG, Lydiard B. Clinical psychopharmacy consultations: acceptance of recommendations on an adult inpatient psychiatric unit. Hosp Pharm. 1995;30(9):786–90.PubMedGoogle Scholar
  34. 34.
    Stanislav SW, Barker K, Crismon ML, Childs A. Effect of a clinical psychopharmacy consultation service on patient outcomes. Am J Hosp Pharm. 1994;51(6):778–81.PubMedGoogle Scholar
  35. 35.
    Suehs BT, Mican LM, Campbell AH. Retrospective evaluation of an inpatient psychiatric pharmacist consultation service. J Am Pharm Assoc. 2011;51(5):599–604.CrossRefGoogle Scholar
  36. 36.
    Stoner SC, Worrel JA, Jones MT, Farrar CA, Ramlatchman LV. Pharmacist-designed and -implemented pharmaceutical care plan for antipsychotic-induced movement disorders. Pharmacotherapy. 2000;20(5):583–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Al-Saffar N, Deshmukh AA, Carter P, Adib SM. Effect of information leaflets and counselling on antidepressant adherence: open randomised controlled trial in a psychiatric hospital in Kuwait. Int J Pharm Pract. 2005;13(2):123–31.CrossRefGoogle Scholar
  38. 38.
    Hazra M, Uchida H, Sproule B, Remington G, Suzuki T, Mamo DC. Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia. Psychiatry Clin Neurosci. 2011;65(7):676–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Thompson A, Sullivan SA, Barley M, Strange SO, Moore L, Rogers P, et al. The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards—a cluster randomized controlled trial. Psychol Med. 2008;38(05):705–15.PubMedCrossRefGoogle Scholar
  40. 40.
    Ved P, Coupe T. Improving prescription quality in an in-patient mental health unit: three cycles of clinical audit. Psychiatr Bull. 2007;31(8):293–4.CrossRefGoogle Scholar
  41. 41.
    Virani A, Crown N. The impact of a clinical pharmacist on patient and economic outcomes in a child and adolescent mental health unit. Can J Hosp Pharm. 2003;56(3):158–62.Google Scholar
  42. 42.
    Alderman CP. A prospective analysis of clinical pharmacy interventions on an acute psychiatric inpatient unit. J Clin Pharm Ther. 1997;22(1):27–31.PubMedCrossRefGoogle Scholar
  43. 43.
    Shaw H, Mackie CA, Sharkie I. Evaluation of effect of pharmacy discharge planning on medication problems experienced by discharged acute admission mental health patients. Int J Pharm Pract. 2000;8(2):144–53.CrossRefGoogle Scholar
  44. 44.
    Dorevitch A, Perl E. The impact of clinical pharmacy intervention in a psychiatric inpatient hospital. J Clin Pharm Ther. 1996;21:45–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887–92.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166(9):955–64.PubMedCrossRefGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2013

Authors and Affiliations

  • Tom E. Richardson
    • 1
    Email author
  • Claire L. O’Reilly
    • 1
  • Timothy F. Chen
    • 1
  1. 1.Faculty of PharmacyThe University of SydneySydneyAustralia

Personalised recommendations